New five-year findings suggest that lecanemab, an Alzheimer's drug not approved for routine NHS use, could offer patients longer-lasting benefits than previously thought, with its apparent advantages increasing over time.
The results, presented at the Clinical Trials on Alzheimer's Disease conference in Boston, indicate that the gap between patients receiving the treatment and those going without widens over several years. This could help people living with the disease maintain their independence for longer, potentially delaying the need for residential care.
Benefits build over time
Researchers assessed patients' memory, thinking skills and everyday abilities using an 18-point scale ranging from no impairment to severe dementia. After 18 months, those receiving lecanemab scored 0.52 points better than comparable untreated patients. This difference increased to one point after three years and 2.05 points after five years.
Scientists from Yale University and drug manufacturer Eisai also found that 61.9 per cent of treated patients progressed to a more advanced stage of Alzheimer's, compared with 77.5 per cent of untreated patients. Their analysis, which accounted for when patients deteriorated, indicated a 36 per cent reduction in the rate of progression to the next stage.
NHS access remains unresolved
Britain became the first European country to license lecanemab in 2024, after trials showed it slowed cognitive decline by 27 per cent over 18 months, equivalent to delaying deterioration by around five to six months. However, NHS funding authorities rejected the treatment after deciding its benefits did not justify the cost.
The original trials lasted just 18 months, leaving questions over its longer-term effectiveness. The longer-term research compared treated patients with similar individuals from two separate studies, rather than a randomly assigned placebo group, meaning differences between the groups could explain some of the apparent benefits.
Dr Sheona Scales, director of research at Alzheimer's Research UK, said: "These are promising findings that suggest the benefits of lecanemab can continue to build with ongoing treatment, offering even more hope for people living with Alzheimer's disease."
"There is growing evidence that lecanemab is able to slow disease progression, particularly when treatment starts during the early stages of the disease. However, it is important to recognise that these latest findings come from a long-term follow-up study, rather than a randomised controlled trial. This data adds further weight to the argument that this treatment should be made available to NHS patients, provided the right data collection is in place."
Impact on patients and next steps
Around one million people across Britain are living with dementia, with Alzheimer's responsible for the majority of cases. Larry Woelk, 79, from Hampshire, has been receiving lecanemab for six years after enrolling in a clinical trial. A total of 1,734 people received treatment during the original trial and its extension, and no new safety concerns were reported despite known risks of serious brain swelling and bleeding.
Earlier this month, Lord Cameron of Chipping Norton, president of Alzheimer's Research UK, joined 48 clinical leaders in calling for urgent action to make new Alzheimer's treatments available on the NHS. Manufacturers remain in talks with health officials over NHS access, while Prime Minister Andy Burnham has announced a £48million dementia research partnership. Mr Burnham, whose father died with Alzheimer's disease in September, has pledged to make dementia research a national priority and wants Britain to lead the search for a cure. The Telegraph also reported plans for a £48million expansion of a UK facility manufacturing the drugs for export, despite NHS patients being denied routine access.